Trackers
Where every science story stands.
A discovery is rarely one day's news. Each tracker follows one question, a disease, a technology, a fight over a policy, as a dated, sourced timeline the morning letter extends, and answers where it stands right now. Every promise made along the way is kept on the record until it is kept, slips, or goes quiet.
- Trackers
- 56
- Moved this week
- 19
- Dated beats
- 276
- Promises tracked
- 15
Life Sciences & Medicine 22
Gene therapy for inherited blindness Moved this week Gene therapy for inherited blindness Where it stands · Oct 5, 2026 A Michigan State University team reported that a single injection of a virus carrying a working CaBP4 gene stopped blindness from progressing in whippets and improved vision, especially in dim light. The treated retinas also expanded the layer that holds the visual connectors, a repair many researchers had thought impossible in adult mammals. The condition is rare and the work is in dogs, so whether it works in people remains untested. Latest · Oct 17, 2026 The Bright Side reported that three adults given a one-time gene therapy for a rare inherited blindness still showed visual gains at 24 months. Only six patients have been treated and Phase 3 has not yet dosed. The many-fronted fight against Alzheimer's Moved this week Is there a treatment for Alzheimer's yet? Where it stands · Oct 2, 2026 The work now spans seven fronts: how tau spreads, drugs that retune the brain's immune cells, blood tests that catch the disease early, genetic risk scores built for different ancestries, the folding of the genome inside brain cells, a placenta-derived nasal spray in mice, and now damage to the brain's blood vessels in APOE4 carriers. Mount Sinai researchers found that blocking TGF-β signaling restored pericyte coverage and cut fibrosis and amyloid in aged APOE4 mice. Nobody has tried blocking TGF-β in a person, so Latest · Oct 17, 2026 Neuroscience News reported that MIT researchers traced how the APOE4 variant traps fats in oligodendrocytes, and a compound that inhibits GSK3b dissolved the droplets and restored myelination in human brain organoids and Alzheimer's mice. Gladstone scientists separately found that gamma waves come from brain cells firing in relays, with one-third staying silent, and that restoring the Nav1.1 channel repaired the timing and rescued cognition in Alzheimer's mice. Nature also reported that the enzyme Pla2g2f is linked to preserved memory in resilient aging brains. The expanding reach of mRNA vaccines Moved this week Can the technology behind the COVID vaccines fight cancer too? Where it stands · Oct 16, 2026 The FDA approved mFlusiva, Moderna's mRNA seasonal flu vaccine for adults 50 and older, after a trial of nearly 41,000 people found it beat a standard flu shot by 26.6 percent. Merck and Moderna say intismeran, a personalized melanoma vaccine, met its primary endpoints in the first randomized Phase 3 trial of its kind, and they are now preparing to file for approval, with trials already running in lung, kidney and bladder cancer. The full melanoma numbers have not been released, and whether it works against 'cold' Latest · Oct 16, 2026 STAT reported that Merck and Moderna are preparing to file intismeran autogene for approval after August's Phase 3 melanoma result, and that trials are already running in adjuvant lung, kidney and bladder cancer. Moderna's Stephen Hoge said the companies 'have a lot of exploring to do and need to prioritize where we explore', since the vaccine has so far been tested only as an add-on after surgery, where Keytruda works best. Ending hepatitis C Moved this week Ending hepatitis C Where it stands · Oct 15, 2026 The RESOLVE trial, published in The Lancet and led by Dr Rakesh Aggarwal, found eight weeks of sofosbuvir-velpatasvir cleared hepatitis C in 410 of 415 people who returned for testing (98.8 percent), against 397 of 401 on the standard twelve weeks (99.0 percent). It enrolled 880 untreated adults without cirrhosis at five Indian hospitals, and guidelines have not changed. People with cirrhosis, HIV or injection drug use were not studied, and whether shorter courses improve completion is not yet measured. Latest · Oct 15, 2026 The RESOLVE trial, published in The Lancet and led by Dr Rakesh Aggarwal, reported that eight weeks of sofosbuvir-velpatasvir cleared hepatitis C in 410 of 415 people who returned for testing, 98.8 percent, against 397 of 401 on the standard twelve weeks, 99.0 percent. The trial enrolled 880 untreated adults without cirrhosis at five public hospitals in Lucknow, New Delhi and Varanasi. Weight-loss drugs and everything else they do Moved this week Do the new weight-loss drugs do more than weight loss? Where it stands · Oct 7, 2026 GLP-1 drugs keep turning up effects that reach beyond the scale, including a possible calorie-burning brown fat mechanism, altered reward-seeking in mice, and now signs of slower biological aging. Novo Nordisk and Eli Lilly reported at a conference that patients on the drugs had aging clocks two to three years younger than placebo, up to 4 years by some measures. These are the companies' own readouts, and no one knows whether the clocks move in people who are not already sick. Latest · Oct 15, 2026 ScienceDaily reported that Ozempic and Wegovy were linked to a rare risk of sudden vision loss. STAT separately covered a new study of how GLP-1 use relates to interactions with the criminal justice system, employment and housing stability. Stopping pancreatic cancer before it starts Moved this week Stopping pancreatic cancer before it starts Where it stands · Oct 14, 2026 Cancer interception is emerging as its own field, aimed at halting abnormal growths before they become tumours. In one vaccine trial, roughly 90 percent of participants with pancreatic abnormalities generated immune cells better able to recognize mutated cells. Whether that immune response prevents cancer in people is not yet known. Latest · Oct 14, 2026 SingularityHub reported that in one cancer-interception vaccine trial, roughly 90 percent of participants with pancreatic abnormalities generated immune cells better able to recognize mutated cells. Muscarinic drugs for schizophrenia Moved this week Muscarinic drugs for schizophrenia Where it stands · Oct 14, 2026 Psychiatric Times is running pieces on muscarinic treatment in psychosis and on emerging schizophrenia mechanisms beyond dopamine, a sign the field is treating the dopamine hypothesis as incomplete. The reporting is commentary and review rather than new trial results. How well muscarinic drugs perform against existing treatments over the long term is not yet established. Latest · Oct 14, 2026 Psychiatric Times published a piece rethinking the dopamine hypothesis around upstream circuits and muscarinic treatment in psychosis, alongside a review of the schizophrenia pipeline and mechanisms beyond dopamine. Regrowing cartilage lost to osteoarthritis Moved this week Can worn-out joint cartilage be regrown? Where it stands · Sep 4, 2026 Stanford researchers traced age-related cartilage loss to a single enzyme, 15-PGDH, and found that blocking it regrew worn cartilage in old mice and prevented arthritis entirely in young mice given the mouse equivalent of a torn ACL. A University of Colorado Boulder team separately reported an injection that returned arthritic animal joints to a healthy state within four to eight weeks. No person has been treated, and the enzyme is active body-wide, so safety is unsettled. Latest · Oct 14, 2026 ScienceAlert reported that an FDA-approved drug could be repurposed to relieve osteoarthritis pain and protect cartilage. Menin and the aging brain's memory Moved this week Menin and the aging brain's memory Where it stands · Oct 13, 2026 Restoring the protein Menin in older mice improved memory, balance, bone mass and skin thickness within 30 days, and the amino acid D-serine improved learning and memory in three weeks. The work dates from 2023 and was done in mice. Whether Menin or D-serine does anything comparable in people is not known. Latest · Oct 13, 2026 ScienceDaily reported that restoring Menin in older mice improved memory, balance, bone mass and skin thickness within 30 days, and that the amino acid D-serine improved learning and memory in three weeks, work from 2023 that is still in mice. AI reading heart disease from routine ECGs Moved this week AI reading heart disease from routine ECGs Where it stands · Sep 22, 2026 An AI model trained on millions of patients read ordinary ECGs from 67,000 people and correctly flagged 81 percent of heart failure cases and 90 percent of heart valve disease cases, catching conditions that normally hide until a cardiac arrest reveals them. The model has been validated on a large retrospective dataset. It has not yet been shown to change patient outcomes in prospective clinical use. Latest · Oct 10, 2026 The NIH reported that a deep learning model reading ECGs already recorded during sleep studies, trained on 15,809 patients and tested on 9,810 and 12,576 more, sorted people by long-term risk of atrial fibrillation, heart failure and death. Optogenetics leaves the lab for patients Active Optogenetics leaves the lab for patients Where it stands · Oct 9, 2026 Optogenetics won the 2026 Nobel Prize in physiology or medicine for Karl Deisseroth, Peter Hegemann and Georg Nagel, and its first clinical use is in vision lost to retinitis pigmentosa. A small trial reported by STAT restored some vision, and the New England Journal of Medicine published a retinitis pigmentosa study the same week. How large and lasting the benefit is has not been established. Latest · Oct 9, 2026 Karl Deisseroth of Stanford, Peter Hegemann and Georg Nagel won this year's Nobel Prize in physiology or medicine for optogenetics. The New England Journal of Medicine published a study the same week on an optogenetic therapy for advanced retinitis pigmentosa, though the coverage did not report the trial's size or results. Jonathan the tortoise and the genes of a long life Active Jonathan the tortoise and the genes of a long life Where it stands · Oct 9, 2026 Researchers led by the longevity nonprofit Kallel sequenced the genome of Jonathan, a 194-year-old Aldabra giant tortoise on St. Helena, and found 287 unique gene variants tied to DNA repair, lower inflammation, insulin regulation and cancer suppression. The switches controlling DNA repair and metabolism looked very similar to those of younger giant tortoises, though the epigenome usually drifts with age. It is one animal with an estimated age, so what the pattern means for other species is not known. Latest · Oct 9, 2026 Researchers led by the longevity nonprofit Kallel reported in Science Advances that Jonathan, a 194-year-old Aldabra giant tortoise, carries 287 unique gene variants tied to DNA repair, lower inflammation, insulin regulation and cancer suppression. The gene switches controlling DNA repair and metabolism in his epigenome looked very similar to those of younger giant tortoises, the first giant-tortoise epigenome on record. Growing human brain tissue inside mouse brains Active Growing human brain tissue inside mouse brains Where it stands · Sep 26, 2026 Scientists have begun replacing sections of the mouse cortex with human brain tissue, an early step toward chimeric brains meant to model neurological disorders directly. PsyPost reported the swap on 2026-09-26, without yet detailing how much of the circuit was human or how it functioned inside a living mouse. It remains unknown how closely these chimeric circuits reproduce a human brain's actual disease processes. Latest · Oct 7, 2026 Nature published a piece arguing that brain organoids grafted into mice that lack a cortex will advance human brain research. Transplanted hearts take on their new host's age Active Transplanted hearts take on their new host's age Where it stands · Oct 4, 2026 Nature reported that months after transplant, DNA methylation in heart tissue moved toward the recipient's biological age instead of the donor's. A Harvard Medical School mouse preprint now shows the same pattern in both directions: older hearts in younger mice read as younger, and younger hearts in older mice aged faster. The authors suggest donor age limits could one day loosen, but the mouse work is not peer reviewed, and whether the shift improves outcomes for patients has not been established. Latest · Oct 4, 2026 A Harvard Medical School team led by Jesse Poganik reported in a bioRxiv preprint, not yet peer reviewed, that after four to six months, older hearts transplanted into younger mice read as biologically younger and younger hearts in older mice showed signs of faster aging. A quote in a weekly roundup said the group saw the same effect in human transplant recipients, with some but not all functional measures tracking the prediction. Treating and preventing long COVID Active Can long COVID be treated or prevented? Where it stands · Sep 4, 2026 Two randomized trials found drugs already in medicine cabinets can cut the odds of developing long COVID when given during the acute infection: Paxlovid by 40 percent within three months, metformin by around half at six months. A Brazilian trial of 399 adults with lasting post-COVID fatigue found fluvoxamine had a high probability of beating placebo. Treating the condition once it has set in still looks hard, and one new study found Paxlovid did not help existing symptoms. Latest · Oct 1, 2026 In a triple-blind, sham-controlled pilot, 15-minute at-home magnetic stimulation headset sessions twice a week for four weeks improved long COVID patients' working memory, processing speed and verbal learning, with gains still present at the eight-week follow-up, Neuroscience News reported. REM sleep and long-term disease risk Active REM sleep and long-term disease risk Where it stands · Sep 24, 2026 A study found people who got more REM sleep had a lower risk of 83 diseases, ScienceDaily reported. This is a headline-level finding so far, and the underlying study's population, methodology and effect sizes are not yet fully known. Latest · Sep 24, 2026 A study found people who got more REM sleep had a lower risk of 83 diseases, ScienceDaily reported. How pregnancy, puberty and menopause reshape the brain Active How pregnancy, puberty and menopause reshape the brain Where it stands · Sep 21, 2026 A team led by cognitive neuroscientist Sophie van 't Hof at Amsterdam University Medical Center scanned more than 1,000 people repeatedly across puberty, pregnancy and menopause and found each phase left a distinct signature: gray matter loss sped up during puberty and pregnancy, consistent with active brain reorganization, while menopause instead paused the brain's normal gradual shrinkage. Participants self-reported their menopause stage and were not tested for hormone levels, so whether falling estrogen and prog Latest · Sep 21, 2026 A team led by Sophie van 't Hof at Amsterdam University Medical Center scanned the brains of more than 1,000 people repeatedly across puberty, pregnancy and menopause and found gray matter loss sped up during puberty and pregnancy, consistent with active reorganization, while the usual gradual shrinkage stopped entirely once menopause began. Lifestyle trials against dementia Active Can exercise and brain training lower dementia risk? Where it stands · Sep 7, 2026 LatAm-FINGERS, a two-year trial of at-risk older adults across 11 Latin American countries, published its full results in The Lancet: structured coaching in exercise and diet, adapted locally in each country rather than simply translated, improved cognition 55% more than general health advice alone. Lead author Lucia Crivelli said the program was built to be practical, affordable and feasible as a public health strategy. It is not yet known whether the gains hold once the coaching stops or translate into fewer deme Latest · Sep 7, 2026 The LatAm-FINGERS trial, published in The Lancet, found that older adults across 11 Latin American countries who received structured coaching improved cognition 55% more than a control group given only general health advice, with country working groups swapping in local forms of exercise like salsa and tango and local foods like avocado, quinoa and chia for the MIND diet. Resetting the body's aging immune cells Active Can the aging immune system be reset? Where it stands · Sep 4, 2026 Stanford researchers found that aging jams the receptor macrophages use to clear out spent immune cells, letting inflammation leak into organs throughout the body. Blocking that one receptor, EP2, in aged mice restored 59 of 71 previously abnormal blood proteins to youthful levels, along with leaner bodies, better grip strength and sharper memory, and the same stuck pattern turned up in older human liver tissue. Blocking EP2 in a person has never been tried. Latest · Sep 4, 2026 A Stanford team led by Katrin Andreasson found that tissue-resident macrophages lose the ability to clear a second immune cell type as animals age, driving body-wide inflammation, and blocking a single receptor on those macrophages in mice produced leaner bodies, sharper memory, stronger hearts and muscles, and younger tissue in the brain, liver, spleen, bone marrow, kidney and colon. A cochlear implant for vision Active Can an implant give sight back in macular degeneration? Where it stands · Sep 4, 2026 Science Corporation's PRIMA retinal implant, a chip smaller than a grain of rice paired with camera-mounted glasses, won European approval for commercial sale, and a 38-patient trial across five countries produced an average gain of 25.5 letters on a standard eye chart. Patients have read a novel and done crossword puzzles, though CEO Max Hodak described the current vision as like looking through a straw. The planned US launch, as soon as 2027, has not happened. Latest · Aug 1, 2026 SingularityHub reported that Science Corporation's PRIMA implant, a chip smaller than a grain of rice paired with camera-mounted glasses, produced an average gain of 25.5 letters, more than five lines, on a standard eye chart across a 38-patient trial in five countries, and the company said the first commercial implants are expected in Germany within weeks. The brain cells that keep memories alive Active Which brain cells decide whether a memory lasts? Where it stands · Sep 4, 2026 Astrocytes, long treated as scaffolding for neurons, look like active gatekeepers of which memories survive. Researchers at the Institute of Basic Science found that mice engineered without the protein ankyrin-2 in their astrocytes formed memories normally but lost all long-term recall within two weeks, and they built a light-activated tool that restored the function in living mice. This is animal and lab work, with no evidence yet that it runs the same way in people. Latest · Jul 8, 2026 Researchers at the Institute of Basic Science found that astrocytes control long-term memory persistence through a protein called ankyrin-2 (Ank2). Mice engineered without Ank2 in their astrocytes formed memories completely normally but lost all long-term recall within two weeks while short-term memory stayed intact. The team also built a light-activated genetic tool called Opto-T1 that restores astrocyte function in living mice and successfully boosted long-term memory persistence. Switching mammal regeneration back on Active Can mammals be made to regrow tissue instead of scarring? Where it stands · Sep 4, 2026 The machinery for regrowing tissue looks silenced in mammals rather than lost. Researchers showed the growth factor FGF2 can redirect scar-forming cells toward regeneration, and mice regrew bone, joint and ligament tissue, building on earlier work that restarted ear regeneration by switching a single gene back on. Epigenetic editing has entered human trials for muscular dystrophy, but the regeneration results themselves are still in mice. Latest · Jun 27, 2026 Epigenetic editing that switches genes on and off without changing the DNA sequence entered human trials for muscular dystrophy.
Natural Sciences 14
The SuperAgers and their protected memory Moved this week Why do some people keep a sharp memory into their nineties? Where it stands · Sep 4, 2026 A University of Chicago and TGen team compared 142 SuperAgers, people in their eighties and nineties with memory as sharp as someone decades younger, to 89 cognitively average older adults and found the two groups genetically indistinguishable on the APOE gene and three polygenic risk scores. Studies in Sardinia and in Rugao, China point instead to daily movement, personal autonomy, low stress and social ties. What actually protects those memories is still unidentified. Latest · Oct 17, 2026 A Massachusetts General Hospital team led by Amar Sahay reported in Nature Neuroscience that activity of the enzyme PLA2G2F rises with age in the human brain and was highest in 'resilient' people whose thinking stayed intact despite amyloid-β deposits. Mice lacking the gene showed more inflammation and neuron degradation as they aged, while mice with extra Pla2g2f had better-connected neurons and scored higher on spatial memory tests. IceCube and the neutrino sky Moved this week IceCube and the neutrino sky Where it stands · Oct 8, 2026 IceCube was the first detector to find neutrinos coming from deep space, after decades of research into these elusive particles. Nature's roundup of the 2026 Nobel Prizes included a hunter of ghost particles. What sources the neutrinos trace back to is still being worked out. Latest · Oct 17, 2026 Nature published a commentary noting that IceCube just won a Nobel prize and urging protection of astroparticle physics projects with the same potential. The orexin discovery reshaping narcolepsy treatment Moved this week The orexin discovery reshaping narcolepsy treatment Where it stands · Sep 24, 2026 Stanford's Emmanuel Mignot is sharing the 2026 Albert Lasker Basic Medical Research Award for discovering in 1999 that the brain chemical orexin governs wakefulness, and researchers have now found orexin neurons also act as an effort-tracking system in the brain, beyond sleep alone. The discovery has already led to new narcolepsy and insomnia drugs, and orexin-replacement compounds like oveporexton are now in development for narcolepsy type 1. It is still unclear how far orexin-based treatment can extend to the muc Latest · Oct 10, 2026 ScienceAlert reported that people with narcolepsy have surprisingly youthful brains, and that scientists do not yet know why. What Enceladus's plume is made of Active What Enceladus's plume is made of Where it stands · Oct 5, 2026 Cassini detected 961 salt-rich ice grains from Enceladus with very different chemistry from one another. Lab freezing experiments show that slow-cooling droplets sort their salts, so a single ocean can produce many kinds of grain. How closely the lab process matches what happens in the moon's vents is not yet established. Latest · Oct 5, 2026 Phys.org reported that Cassini saw 961 salt-rich ice grains from Enceladus with very different chemistry, and that lab freezing experiments show slow-cooling droplets sort their salts, so one ocean can produce many kinds of grain. The undruggable protein problem Active Can drugs finally hit the proteins once called undruggable? Where it stands · Sep 4, 2026 The FDA approved daraxonrasib, sold as Rasonque, for advanced pancreatic cancer in August after a trial found patients lived a median of 13.2 months versus 6.7 months on standard chemotherapy. It works around KRAS, the gene behind more than 90 percent of pancreatic tumors and long thought too smooth a surface for any drug to grip, by binding a molecule called cyclophilin A. Whether tumors develop resistance to it the way they do to chemotherapy is not yet known. Latest · Oct 3, 2026 Scripps researchers built a small computer-designed protein that binds the membrane-spanning region of TLR4, an inflammation-linked immune receptor with no FDA-approved drug aimed squarely at it, and blocks its inflammatory signaling. The Nancy Grace Roman Space Telescope Active Did the new NASA space telescope launch and does it work? Where it stands · Sep 21, 2026 The Nancy Grace Roman Space Telescope launched August 31 and NASA has since extended its planned mission life from 10 to 22 years, having found it carries about double the propellant originally expected. Its camera has now returned a first test image, unfocused lime-green starlight, on the way to its gravitationally stable point a million miles from Earth, but no science images have been returned yet. Latest · Sep 21, 2026 The Nancy Grace Roman Space Telescope's 300-megapixel camera returned its first test image on the way to its L2 parking spot beside the James Webb Space Telescope, showing lime-green loops of unfocused starlight. A gut bacterium that hunts tumors Active Can a gut bacterium be used to attack tumors? Where it stands · Sep 4, 2026 A team at the Japan Advanced Institute of Science and Technology screened 45 bacterial strains from the guts of tree frogs, newts and lizards and found one, Ewingella americana, that cleared colorectal tumors in mice. A single intravenous dose produced a 100 percent complete response rate, beating both a checkpoint-inhibitor drug and the chemotherapy used for comparison. It has been tested in mice, in one cancer type, and no person has received it. Latest · Sep 21, 2026 ScienceAlert reported that a separately engineered probiotic wiped out 43 percent of colorectal tumors in mice, a second bacterial approach targeting the same cancer type as the Ewingella americana work. Restoring sight without an implant Active Can eyesight be restored without an implant? Where it stands · Sep 9, 2026 A consortium led by the Institute for Bioengineering of Catalonia made light-activated compounds, named prosthe6, that restored light perception and visually guided behavior in blind mice and zebrafish by waking retinal circuitry that survives after photoreceptors die, and two variants worked simply as eye drops, no injection or implant needed. Separately, a blind woman injected with her own muscle mitochondria saw her pupils respond to light again, though the effect faded after about four weeks. Macular degenerati Latest · Sep 9, 2026 The Optimist Daily reported that IBEC's light-activated eye drop compounds are named prosthe6, with two variants, prosthe6-12 and prosthe6-15, working as simple eye drops with no injection or implant; in blinded zebrafish larvae and mice modeling macular degeneration and retinitis pigmentosa, the drops restored reflexive eye movements and light-avoidance behavior within days at light levels no stronger than an overcast afternoon. Clean air zones show up in children's lungs Active Do clean air zones actually improve children's lungs? Where it stands · Sep 4, 2026 London's Ultra Low Emission Zone is the first clean air scheme shown to change how children's lungs grow, not just what the monitors read. A Lancet Public Health study of 3,414 school children found better lung growth inside the zone five years after roadside nitrogen dioxide fell 54 percent, and the share of Central London children with impaired lung function fell from 14 percent to 9 percent. Luton is an imperfect comparison town, and no other city has shown the same. Latest · Sep 1, 2026 Queen Mary University researchers reported that annual lung capacity gains in London's ultra low emission zone children rose to 233 milliliters a year, overtaking the 223 milliliters recorded in the Luton comparison group that had started out with cleaner air, and the share of Central London children with impaired lung function fell from 14 percent to 9 percent over the same period. Black holes too massive for the young universe Active How did the first black holes get so big so fast? Where it stands · Sep 4, 2026 Telescopes keep finding black holes from the universe's first billion years that already hold billions of times the mass of the sun. The Euclid telescope found 31 of the oldest quasars ever detected, and co-author Joseph Hennawi said astronomers do not yet understand how they grew so massive so fast. No accepted mechanism explains that growth, so the fossil record is running well ahead of the theory. Latest · Aug 15, 2026 A team led by MIT's Rohan Naidu reported in Nature on August 12 the discovery of MoM-BH*-1, a black hole roughly 100,000 times the mass of the sun wrapped in a dense hydrogen envelope that mimics a star, glowing about 100 billion times brighter than any star could, only a few hundred million years after the Big Bang. The find may explain the mysterious little red dots that keep appearing and then vanishing in deep JWST images. Ghost ancestor lineages in human DNA Active Are there lost human ancestors hiding in our DNA? Where it stands · Sep 4, 2026 A team led by Priya Moorjani at UC Berkeley scanned more than 500 modern human genomes and found two previously unknown archaic lineages that interbred with our ancestors, one of which left DNA in every person alive today, contributing about 1% of the genome. A Science study using the same fossil-free method suggests those lineages are Homo heidelbergensis and Homo erectus. What the surviving gene regions actually do in people has not been established. Latest · Aug 3, 2026 A Science study using a new fossil-free detection method found the ghost lineage carried by everyone alive today likely belongs to Homo heidelbergensis, while the super-archaic lineage found in Oceanian populations likely belongs to Homo erectus, and both archaic gene regions concentrate in parts of the genome tied to immune function and metabolism. The quantum advantage race Active Can quantum computers actually beat regular computers yet? Where it stands · Sep 4, 2026 Classical hardware keeps catching up. Joseph Tindall and Miles Stoudenmire at the Flatiron Institute used tensor networks to reproduce on a personal laptop results a team had claimed required a quantum computer to model. On the hardware side, a group in Austria and Munich entangled two distant qubits automatically using a shared low-energy microwave bath, tested across about 20 inches of cable. Whether that entanglement holds at any useful distance is untested. Latest · Jul 29, 2026 A team at the Institute of Science and Technology Austria and the Technical University of Munich confirmed a 20-year-old theory by entangling two distant qubits automatically using a shared low-energy microwave bath, with no active photon-matching required, testing it across about 20 inches of cable. Building a living cell from parts Active Can scientists build a living cell from scratch? Where it stands · Sep 4, 2026 The minimal genome work has held up: JCVI-syn3.0 runs on just 473 genes, and a synthetic cell nicknamed SpudCell was reported growing, copying its DNA and dividing, though only about 30 percent still carried DNA after five generations. The synthetic yeast consortium finished all 16 chromosomes about five years past the 2018 target it set itself. Combining them into a single fully synthetic yeast cell is still unfinished. Latest · Jul 2, 2026 A synthetic cell nicknamed SpudCell was reported growing, copying its DNA and dividing, with about 30 percent still carrying DNA after five generations. Our ancient relatives, still in our genes Active Does Neanderthal and Denisovan DNA still shape our immune systems? Where it stands · Sep 4, 2026 Genes picked up from Neanderthals and Denisovans are still doing work in modern immune systems, sometimes raising disease risk and sometimes lowering it. One Neanderthal stretch on chromosome 12 lowers the risk of severe COVID-19 by around 22 percent, and researchers have now catalogued more than 3,000 Denisovan variants active in modern immune cells. Which ancient pathogens drove those variants is still unknown. Latest · Jun 19, 2026 Researchers catalogued more than 3,000 Denisovan genetic variants active in modern immune cells, with some Papua New Guinean populations carrying up to about 5 percent Denisovan DNA.
Technology & Innovation 8
The clean-energy tipping point Moved this week Is clean energy winning? Where it stands · Sep 15, 2026 Solar generated more US electricity than coal for the first time in the country's history, and global solar capacity reached roughly 3 terawatts in early 2026, with wind and solar together supplying 22 percent of global electricity by April 2026. Cheap panels, mostly made in China, have pushed solar into millions of individual homes, small businesses and factories, cutting bills and bringing reliable power to places grids never reached. Grids engineered for one-way power flow are struggling to keep pace with that s Latest · Oct 16, 2026 The Bright Side reported that Australia's Clean Energy Regulator table shows 5,358 megawatts of utility-scale wind and solar reaching final investment decision from 1 January to 30 September 2026, already above the previous full-year high of 4,884 megawatts in 2018 and well above 2,124 in 2025. The September quarter added 2.1 gigawatts, including a record 1.1 gigawatts of wind, though former Clean Energy Finance Corporation head Ian Learmonth has said the 2030 target implies about 6.3 gigawatts of new large-scale generation a year. Anthropic's AI biolab finds a new CRISPR-like system Active Anthropic's AI biolab finds a new CRISPR-like system Where it stands · Sep 26, 2026 Anthropic's AI biolab reported that agents mining viral and phage genomes for new biology surfaced a previously undescribed CRISPR-like DNA system, an early sign that an AI research agent can produce a genuinely novel finding rather than just synthesize known results. Nature covered the find on 2026-09-26, noting outside researchers still need to confirm it functions as claimed. It is not yet known how many of the AI biolab's other proposed discoveries will hold up under wet-lab testing. Latest · Sep 26, 2026 Nature reported that Anthropic's AI biolab, mining viral and phage genomes for new biology, identified a previously unknown CRISPR-like DNA system in viruses. CAR T cell therapy takes aim at solid tumors Active Can engineered immune cells work against solid tumors? Where it stands · Sep 23, 2026 CAR T cell therapy is showing durable results against solid tumors on more than one front. Beyond the GPNMB-targeted glioblastoma work, a Baylor College of Medicine team used a 3-year-old boy's own reprogrammed immune cells to clear metastatic liver cancer that had resisted surgery and chemotherapy twice, and he remained cancer-free a year later. Both results rest on a single patient each, so durability and repeatability in a larger group are still unproven. Latest · Sep 23, 2026 A Baylor College of Medicine team engineered CAR T cells from a 3-year-old boy's own immune cells, with a built-in kill switch, to treat metastatic liver cancer that had returned twice after surgery and chemotherapy. Two infusions cleared his tumors and he remained cancer-free a year later with no serious side effects, treated entirely as an outpatient. Brain implants leave the lab Active Can brain implants give paralyzed people movement and speech back? Where it stands · Sep 15, 2026 Brain-computer interfaces are starting to restore more than one channel of expression at once. A UCSF team led by Edward Chang showed three paralyzed patients could control a full-body avatar that spoke and gestured together, with two of them managing both in real time, while Feinstein Institutes researchers separately reported a double neural bypass raising one patient's arm strength by up to 86 percent after 35 weeks of training. These remain single-digit patient counts inside research trials, and how long any of Latest · Sep 15, 2026 A UCSF team led by neurosurgeon Edward Chang tested a brain-computer interface on three patients with vocal-tract and body paralysis from ALS or brainstem stroke, reading motor cortex signals for both speech and gestures at once. Two participants controlled a full-body avatar in real time, speaking and gesturing together, and the combined brain activity for speech plus gesture exceeded the sum of the two signals alone rather than overwhelming the system as researchers had assumed. Europe's push into private orbital launch Active Europe's push into private orbital launch Where it stands · Sep 11, 2026 Isar Aerospace's Spectrum rocket launched from Andoya Spaceport in Norway on its second attempt and released five CubeSats and a technology experiment into orbit, the first successful orbital launch by a privately built European rocket. The company has five more Spectrum rockets in production, a factory near Munich nearing completion, and roughly 10 billion euros in customer deals lined up. Scaling to the 40 launches a year the company hopes for is a much larger, unproven engineering and manufacturing challenge. Latest · Sep 12, 2026 Ars Technica reported that Isar Aerospace, founded in 2018 by three students at a German university, spent roughly $1 billion in private financing over eight years before Spectrum's successful second launch attempt, and that satellite operator Astroscale had already signed a launch contract with Isar before the rocket ever reached orbit. AI's disputed rise in pure mathematics Active AI's disputed rise in pure mathematics Where it stands · Sep 12, 2026 AI systems keep producing claimed proofs of hard mathematical problems, but the field is increasingly divided over whether to trust them. The world's top 25 Fields Medalists have warned that machine-generated proofs are undermining rigor in the hardest areas of math, and OpenAI's latest claimed result triggered fresh disputes over credit, ethics and privacy. It is still unclear how much of AI's contribution can be verified independently of the companies making the claims. Latest · Sep 12, 2026 The world's top 25 Fields Medalists warned that machine-generated proofs are undermining rigor in mathematics' hardest problems, while OpenAI claimed another major mathematical result amid disputes over credit, ethics and privacy. Humanoid robots enter the operating room Active Can humanoid robots perform surgery? Where it stands · Sep 4, 2026 A UCSD team completed the first surgeries done by teleoperated humanoid robots, including a gallbladder removal with a surgeon assisting one robot and a second procedure with two robots working together, both on large nonprimate animals. The robots stand five feet tall and weigh 27 kilograms, against the hundreds of kilograms of conventional systems. The Nature study said plainly that precision, force sensing in soft tissue and clinical safety remain unsolved. Latest · Jul 9, 2026 A UCSD team completed the first surgeries using teleoperated humanoid robots, including a gallbladder removal with a surgeon assisting a single robot and a second procedure with two robots working together on large nonprimate animals. The peer-reviewed study in Nature evaluated the platform across benchtop characterization, dry-lab user studies, and live porcine trials, and was explicit that precision, force sensing in soft tissue, and clinical safety are challenges that remain unsolved before any move toward human patients. A vaccine for coronaviruses we have not met Active Can one vaccine cover coronaviruses that have not appeared yet? Where it stands · Sep 4, 2026 A University of Cambridge group used AI to find the parts of the sarbecovirus family, which includes SARS and COVID-19, that a virus cannot mutate away without losing fitness, and built a fridge-stable DNA vaccine around them that has entered human trials. The older mosaic-8 nanoparticle from Oxford and Caltech, promised a first human trial in 2024, still had no confirmed first dosing in the public record as of mid-2026. No broad vaccine has yet shown it protects anyone. Latest · Jul 8, 2026 Researchers at the University of Cambridge used AI to scan genetic data from thousands of sarbecoviruses, identify conserved targets a virus is unlikely to mutate without losing fitness, and design a DNA vaccine stable without refrigeration and delivered via needle-free high-pressure liquid injection. The vaccine entered human trials for the first time, aiming to protect against the entire sarbecovirus family including strains that do not yet exist.
Solutions & Good News 5
Highway bridges for wildlife Moved this week Highway bridges for wildlife Where it stands · Oct 17, 2026 Colorado's I-25 wildlife overpass, the largest in North America, cut animal-vehicle collisions on its stretch by 91 percent in its first ten months, with elk, moose, pronghorn and bears using it. The figure covers the whole system of five underpasses, fencing and the bridge, not the bridge alone. Ten months is a short record, and it is not yet known whether the drop holds over several years or repays the cost. Latest · Oct 17, 2026 Good News Network reported that ten months after opening, the I-25 overpass near Larkspur, Colorado had cut animal-vehicle collisions by 91 percent against a projection of 90 percent. Wildlife crashes on that stretch used to average one per day, traffic delays fell 9 percent, and a pronghorn crossing was the first documented on the corridor in 30 years. Colorado is now scouting six more crossing sites, including the first overpass designed for Rocky Mountain bighorn sheep. Aldabra's giant tortoise comeback Moved this week Aldabra's giant tortoise comeback Where it stands · Oct 12, 2026 The Seychelles Islands Foundation and the University of Exeter estimated almost 183,000 adult and sub-adult giant tortoises on Aldabra Atoll from counts made between 2018 and 2022, the highest figure on record and the first update to the 100,000 figure cited since the late 1990s. The population looked relatively stable over those years, so the number is a new baseline, not a growth curve. Whether removing feral cats and black rats would lift the remaining limits on growth is not known. Latest · Oct 12, 2026 The Seychelles Islands Foundation and the University of Exeter analyzed five years of counts from 2018 to 2022 and estimated almost 183,000 adult and sub-adult giant tortoises on Aldabra Atoll, the highest figure on record and the first update to the 100,000 figure cited since the late 1990s. The team modeled animals it could not see in dense vegetation, and the population looked relatively stable over the study years. Beavers rewilding drought-stressed rivers Active Beavers rewilding drought-stressed rivers Where it stands · Sep 28, 2026 Utah State University began relocating nuisance beavers into the drought-stressed Price River in 2019, and six years later the river holds its healthiest water levels in years with thriving fish populations. The project has since spread to other Utah watersheds. It is not yet documented how the approach performs outside Utah or under harsher drought conditions. Latest · Oct 3, 2026 Upworthy reported that a pictograph of a beaver on a Tule River rock shelter helped spark California's first beaver restoration since the 1950s, which had grown to 28 relocated beavers at five sites by September 2024. Smell-based pesticide repellents for honeybees Active Smell-based pesticide repellents for honeybees Where it stands · Sep 28, 2026 UC Riverside's Anandasankar Ray screened more than 50 million compounds by machine learning for odors bees avoid, narrowed the field to about 130 candidates, and confirmed in field trials that seven reliably kept foraging bees away from treated combs without harming them. A patent application has been filed, but the compounds have not yet been deployed commercially. Latest · Sep 28, 2026 UC Riverside's Anandasankar Ray built a machine-learning model that screened more than 50 million compounds for bee-repellent odors, narrowed the field to about 130 candidates, and confirmed in field trials with freely foraging bees that seven of the compounds reliably kept bees away from treated combs without harming them, with a patent application already filed. Bringing apex predators back from the brink Active Are wolves and tigers coming back to the wild? Where it stands · Sep 4, 2026 North Carolina's wild red wolf population, down from around 120 to 130 animals in 2011 to fewer than 30, produced four litters and 23 pups this year, with roughly 12 to 16 expected to survive their first months. In Kazakhstan, a female Amur tiger named Hope was released into an unfenced reserve after a decade of reforestation and rebuilding of prey species. Whether this year's pups live long enough to rebuild the population is not yet known. Latest · Aug 18, 2026 One Green Planet reported that North Carolina's wild red wolf population, which collapsed from around 120 to 130 animals in 2011 to fewer than 30 after gunshots, vehicle strikes and coyote hybridization, produced four litters and 23 pups this year, with roughly 12 to 16 expected to survive their first months.
Psychology & Behavioral Science 4
Psilocybin's move into the clinic Moved this week Is psilocybin turning into real medicine? Where it stands · Sep 22, 2026 Psilocybin trials are multiplying and industry is buying in, with Eli Lilly agreeing to acquire the psychedelics biotech AtaiBeckley and Compass Pathways' COMP360 now meeting its primary endpoint in a second Phase 3 depression trial. A separate Oxford trial of 59 depressed patients found both psilocybin and the SSRI escitalopram reduced the brain's negative interpretation bias, the first evidence the two treatments may relieve depression through a shared mechanism despite psilocybin's faster onset. What still is no Latest · Oct 17, 2026 PsyPost reported a small Oregon study testing a cheaper group model of psilocybin therapy for low-income adults in the state's regulated program. Depression scores dropped after two group dosing sessions, but with no comparison group the role of psilocybin itself is unproven. The brain's two separate lineages Moved this week The brain's two separate lineages Where it stands · Sep 23, 2026 A Stanford Medicine study published September 18 in Nature Neuroscience found, using both mouse and human stem cells, that the forebrain and midbrain arise from one population of neural progenitor cells and the hindbrain from an entirely separate one, each carrying a distinct chromatin landscape from remarkably early in development. This overturns the long-standing assumption of one progenitor lineage that diverges late. It is not yet known what this means for how the brain recovers from injury or why certain condi Latest · Oct 17, 2026 Live Science reported on the Stanford finding in mouse embryos that the front and back of the brain come from two separate cell populations. The coverage said the split may explain why hindbrain neurons have been so hard to grow in the lab. Metabolic interventions for mental illness Active Can changing your diet ease schizophrenia or bipolar disorder? Where it stands · Sep 4, 2026 A UCSF randomized controlled trial found a ketogenic diet reduced clinical symptoms of schizophrenia and bipolar disorder, with the gains holding after researchers controlled for weight loss. In that trial 83 percent of patients maintained ketosis through the one-month primary phase, and higher blood ketone levels tracked with sharper drops in depression scores. A McLean Hospital and Harvard trial in first-episode bipolar disorder is not due to report until late 2027. Latest · Oct 1, 2026 Psychiatric Times ran pieces on ketogenic metabolic therapy as an adjunct in serious mental illness and on metabolic psychiatry integrating nutritional and pharmacological interventions. Cash aid and children's biological aging Active Cash aid and children's biological aging Where it stands · Sep 22, 2026 Researchers with the Baby's First Years project found that children of mothers given a larger unconditional monthly cash gift were aging more slowly, measured by DNA methylation using the DunedinPACE algorithm, than children in a comparison group receiving a smaller amount. The effect showed up only in the children, not in the mothers who received the same cash. It is the first evidence that relieving poverty, even partially, can slow the biological aging clock poverty is known to speed up, though why the effect sp Latest · Sep 22, 2026 Researchers with the Baby's First Years project found that children of mothers given the larger monthly unconditional cash gift showed slower biological aging by the DunedinPACE DNA methylation measure than children in the comparison group, an effect that appeared in the children but not the mothers.
Plant-Based & Vegan 3
The gap between opinion and factory farming Moved this week Is farm animal welfare policy catching up with public opinion? Where it stands · Sep 4, 2026 The gap is closing in places and widening in others. Brazil banned both the production and sale of foie gras, and the US share of cage-free eggs rose from under 20 percent in 2018 to 45.7 percent by July 2025 as producers moved to keep selling into California under Proposition 12. Over the same stretch JBS, the world's largest meat company, dropped its net-zero and deforestation commitments, and most farmed animals are still raised on factory farms. Latest · Oct 13, 2026 Plant Based News reported a 2,000-person UK survey in which 65 percent called factory farming unacceptable even though 82 percent identified as meat-eaters, and opposition to greyhound racing rose from 55 to 60 percent since 2024. Ending the killing of male chicks Active Ending the killing of male chicks Where it stands · Sep 19, 2026 In-ovo sexing is running commercially in the United States and Brazil, and Canada has developed methods that can determine sex as early as day four of incubation. Norway adopted the technology in 2023 and has committed to ending chick culling entirely by July 2027, Switzerland began its own transition in 2025, and Germany and France have already banned culling outright. It is not yet clear whether larger egg-producing countries like the US and Brazil will commit to a phase-out timeline of their own rather than only Latest · Sep 19, 2026 Mercy For Animals reported that Norway adopted in-ovo chick sexing in 2023 and has committed to phasing out chick culling entirely by July 2027, that Switzerland began its own transition to the technology in 2025, and that more than 70 percent of surveyed US consumers said the industry should find an alternative to killing day-old male chicks. Engineering myoglobin for plant-based meat Active Can plant-based meat get real meat flavor without an animal? Where it stands · Sep 4, 2026 Belgian startup Paleo engineers a food yeast to make bioidentical myoglobin, the iron-rich protein behind meat's color and savory flavor, and raised a 2 million euro round to fund US and Canadian regulatory filings and formulation trials, after cutting production costs 613-fold since 2020. An Imperial College London team separately got lettuce and tobacco plants to make myoglobin at roughly a tenth of beef's level. Neither has cleared a regulator or reached a shelf. Latest · Sep 2, 2026 Belgian startup Paleo raised a 2 million euro ($2.3 million) round led by Beyond Impact to fund US and Canadian regulatory filings and formulation trials for its fermentation-made, bioidentical myoglobin, after cutting production costs 613-fold since 2020.
Every beat was reported in our daily letter on its date and links onward to the primary study. A tracker is opened only when a story comes back a second time, never for a single day's headline. Every promise stays on the record until it is kept, slips, or passes its own date with no word, and silence is reported as silence, never as failure.
The trackers move every morning.
The day's real progress in science, medicine and beyond, every morning. When a tracker advances, you'll already know. Free, every day.
Free for good. One click to leave.